
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4586567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 2 multiâ€institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 1128-1137.	4.1	447
2	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. Journal of Clinical Oncology, 2014, 32, 513-518.	1.6	375
3	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer, 2009, 115, 665-672.	4.1	353
4	Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. Annals of Surgery, 2012, 256, 965-972.	4.2	325
5	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 320-323.	0.8	308
6	Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 678-686.	0.8	308
7	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of Clinical Oncology, 2022, 40, 2546-2556.	1.6	292
8	Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies. International Journal of Radiation Oncology Biology Physics, 2010, 78, 486-493.	0.8	279
9	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 181-188.	0.8	230
10	Pathologic stage is most prognostic of diseaseâ€free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008, 113, 57-64.	4.1	228
11	Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection. Annals of Surgery, 2009, 249, 236-242.	4.2	206
12	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 513-519.	4.9	186
13	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	6.3	179
14	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 2677-2694.	1.6	169
15	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 3512-3521.	1.5	135
16	Intensityâ€modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer, 2011, 117, 3342-3351.	4.1	132
17	Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1580-1586.	0.8	128
18	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e194-e203.	3.8	126

#	Article	IF	CITATIONS
19	A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum. Annals of Surgical Oncology, 2014, 21, 2956-2962.	1.5	123
20	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2019, 9, 322-332.	2.1	121
21	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
22	Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 901-908.	0.8	114
23	EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with). Gastrointestinal Endoscopy, 2010, 71, 1204-1210.	1.0	110
24	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. Practical Radiation Oncology, 2014, 4, 82-89.	2.1	103
25	Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncológica, 2012, 51, 575-583.	1.8	102
26	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. Diseases of the Colon and Rectum, 2008, 51, 147-153.	1.3	100
27	Correction of motion artifacts in coneâ€beam CT using a patientâ€specific respiratory motion model. Medical Physics, 2010, 37, 2901-2909.	3.0	97
28	Intensity-modulated radiotherapy for lymphoma involving the mediastinum. International Journal of Radiation Oncology Biology Physics, 2005, 62, 198-206.	0.8	96
29	Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 364-368.	1.3	92
30	Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer. Technology in Cancer Research and Treatment, 2007, 6, 31-36.	1.9	86
31	Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 875-879.	1.1	80
32	Comparison of intensityâ€modulated radiotherapy and 3â€dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer, 2010, 116, 3943-3952.	4.1	76
33	Cancer and Fertility Program Improves Patient Satisfaction With Information Received. Journal of Clinical Oncology, 2016, 34, 1780-1786.	1.6	75
34	Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. International Journal of Radiation Oncology Biology Physics, 2002, 54, 170-176.	0.8	68
35	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. Annals of Surgical Oncology, 2013, 20, 1179-1184.	1.5	66
36	Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiotherapy and Oncology, 2015, 116, 149-155.	0.6	66

#	Article	IF	CITATIONS
37	Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 5240-5247.	1.6	65
38	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. Annals of Surgery, 2012, 256, 111-116.	4.2	63
39	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	4.5	63
40	Optimize and refine therapeutic index in radiation therapy: Overview of a century. Cancer Treatment Reviews, 2016, 45, 58-67.	7.7	60
41	Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of Clinical Oncology, 2021, 39, 2803-2815.	1.6	58
42	Intensity-modulated Radiation Therapy for Anal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 8-12.	1.3	57
43	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	1.1	55
44	Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease. Annals of Surgical Oncology, 2012, 19, 1663-1669.	1.5	52
45	Neural network dose models for knowledgeâ€based planning in pancreatic <scp>SBRT</scp> . Medical Physics, 2017, 44, 6148-6158.	3.0	52
46	Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiotherapy and Oncology, 2014, 113, 29-34.	0.6	47
47	Dosimetric analysis of a simplified intensity modulation technique for prone breast radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 95-102.	0.8	46
48	Role of radiation therapy in the management of pancreatic cancer. Journal of Surgical Oncology, 2013, 107, 86-96.	1.7	46
49	An evaluation of motion mitigation techniques for pancreatic SBRT. Radiotherapy and Oncology, 2017, 124, 168-173.	0.6	45
50	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1087-1095.	0.8	44
51	Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer Journal of Clinical Oncology, 2017, 35, 1-1.	1.6	44
52	Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 548-554.	0.8	43
53	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiotherapy and Oncology, 2020, 148, 194-200.	0.6	43
54	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis. Radiotherapy and Oncology, 2013, 107, 189-194.	0.6	41

#	Article	IF	CITATIONS
55	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. Clinical Cancer Research, 2019, 25, 2185-2193.	7.0	41
56	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology, 2020, 10, e136-e146.	2.1	41
57	Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 173-179.	1.3	40
58	The Effectiveness of a Pneumatic Compression Belt in Reducing Respiratory Motion of Abdominal Tumors in Patients Undergoing Stereotactic Body Radiotherapy. Technology in Cancer Research and Treatment, 2014, 13, 259-267.	1.9	39
59	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncológica, 2017, 56, 1746-1753.	1.8	38
60	Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer, 2018, 18, 958.	2.6	38
61	Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Cancer Research, 2021, 81, 3255-3269.	0.9	37
62	Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy, 2003, 2, 139-146.	0.5	36
63	Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35, 277-288.	5.9	35
64	Does preâ€operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase postâ€operative morbidity? A caseâ€matched analysis. Hpb, 2013, 15, 574-580.	0.3	34
65	Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base. Cancer, 2017, 123, 228-236.	4.1	34
66	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiation Oncology, 2019, 14, 114.	2.7	34
67	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118, 5414-5423.	4.1	33
68	A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. Translational Oncology, 2017, 10, 760-765.	3.7	33
69	Modeling Pancreatic Tumor Motion Using 4-Dimensional Computed Tomography and Surrogate Markers. International Journal of Radiation Oncology Biology Physics, 2015, 91, 579-587.	0.8	31
70	Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2016, 121, 252-257.	0.6	31
71	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Japanese Journal of Clinical Oncology, 2018, 48, 458-466.	1.3	31
72	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. Journal of Clinical Oncology, 2015, 33, 1737-1744.	1.6	30

#	Article	IF	CITATIONS
73	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer, 2016, 122, 2083-2090.	4.1	30
74	Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. Practical Radiation Oncology, 2016, 6, 78-85.	2.1	30
75	Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal. Diseases of the Colon and Rectum, 2011, 54, 1090-1097.	1.3	29
76	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. Annals of Surgical Oncology, 2014, 21, 1130-1137.	1.5	29
77	Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer, 2017, 123, 3402-3409.	4.1	29
78	Multicentre results of stereotactic body radiotherapy for secondary liver tumours. Hpb, 2013, 15, 851-857.	0.3	28
79	Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 119-24.	0.7	28
80	Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncológica, 2016, 55, 208-216.	1.8	27
81	Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 237-242.	2.0	26
82	Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. Practical Radiation Oncology, 2016, 6, 166-175.	2.1	26
83	The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. Journal of Surgical Oncology, 2012, 106, 647-650.	1.7	25
84	Stereotactic Body Radiotherapy for Liver Metastases. Seminars in Radiation Oncology, 2017, 27, 240-246.	2.2	25
85	Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection*. Acta Oncológica, 2017, 56, 384-390.	1.8	24
86	The Clinical and Dosimetric Impact of Real-Time Target Tracking in Pancreatic SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 268-275.	0.8	24
87	Longâ€ŧerm outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. British Journal of Haematology, 2012, 159, 329-339.	2.5	22
88	Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. Brachytherapy, 2013, 12, 463-470.	0.5	22
89	Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: A feasibility study. Medical Physics, 2014, 41, 071906.	3.0	22
90	Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecologic Oncology, 2010, 119, 237-242.	1.4	21

#	Article	IF	CITATIONS
91	ACR Appropriateness Criteria®  Resectable Rectal Cancer. Radiation Oncology, 2012, 7, 161.	2.7	21
92	From phaseâ€based to displacementâ€based gating: a software tool to facilitate respirationâ€gated radiation treatment. Journal of Applied Clinical Medical Physics, 2009, 10, 132-141.	1.9	20
93	Quality Assurance for Radiotherapy: A Priority for Clinical Trials. Journal of the National Cancer Institute, 2013, 105, 376-377.	6.3	20
94	Pancreatic cancer and SBRT: A new potential option?. Reports of Practical Oncology and Radiotherapy, 2015, 20, 377-384.	0.6	20
95	Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunology, Immunotherapy, 2021, 70, 989-1000.	4.2	20
96	Positron Emission Tomography Imaging for Gastroesophageal Junction Tumors. Seminars in Radiation Oncology, 2013, 23, 10-15.	2.2	19
97	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 2016, 6, 417-424.	2.1	19
98	Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensityâ€modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. Journal of Surgical Oncology, 2018, 117, 1073-1083.	1.7	19
99	Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2022, 28, 1013-1026.	7.0	19
100	Rapid estimation of 4DCT motionâ€artifact severity based on 1D breathingâ€surrogate periodicity. Medical Physics, 2014, 41, 111717.	3.0	18
101	Advances in the Management of Anal Cancer. Current Oncology Reports, 2016, 18, 20.	4.0	18
102	Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clinical Cancer Research, 2019, 25, 3352-3365.	7.0	18
103	Predicting complete response: is there a role for non-operative management of rectal cancer?. Journal of Gastrointestinal Oncology, 2015, 6, 241-6.	1.4	18
104	Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. Quality of Life Research, 2018, 27, 97-103.	3.1	17
105	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e88-e95.	3.8	17
106	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	1.6	17
107	Intraoperative high-dose-rate brachytherapy using dose painting technique: Evaluation of safety and preliminary clinical outcomes. Brachytherapy, 2013, 12, 1-7.	0.5	16
108	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. Hpb, 2021, 23, 1072-1083.	0.3	16

#	Article	IF	CITATIONS
109	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e194-e203.	3.8	16
110	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British Journal of Cancer, 2015, 113, 1658-1665.	6.4	15
111	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Advances in Radiation Oncology, 2018, 3, 34-41.	1.2	15
112	Positron-Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	1.1	15
113	SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy Journal of Clinical Oncology, 2022, 40, TPS374-TPS374.	1.6	15
114	Neoadjuvant Radiation Therapy Prior to Total Mesorectal Excision for Rectal Cancer is Not Associated with Postoperative Complications Using Current Techniques. Annals of Surgical Oncology, 2014, 21, 2295-2302.	1.5	14
115	Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 235-243.	4.9	14
116	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. Annals of Surgical Oncology, 2017, 24, 251-256.	1.5	14
117	Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1203-1210.	4.9	14
118	Performance of a Nomogram Predicting Disease-Specific Survival After an RO Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 624-629.	0.8	13
119	Kilovoltage Imaging of Implanted Fiducials to Monitor Intrafraction Motion With Abdominal Compression During Stereotactic Body Radiation Therapy for Gastrointestinal Tumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1042-1049.	0.8	13
120	Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 129-36.	0.7	13
121	Anal Cancer: Emerging Standards in a Rare Disease. Journal of Clinical Oncology, 2022, 40, 2774-2788.	1.6	13
122	Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 2168-2178.	1.5	12
123	Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas, 2017, 46, 904-912.	1.1	12
124	Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key. Journal of Clinical Oncology, 2015, 33, 3082-3084.	1.6	11
125	Distribution of FDC-avid nodes in esophageal cancer: implications for radiotherapy target delineation. Radiation Oncology, 2016, 11, 156.	2.7	11
126	Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma Journal of Clinical Oncology, 2017, 35, 4007-4007.	1.6	11

#	Article	IF	CITATIONS
127	Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 97, 924-930.	0.8	10
128	Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. Brachytherapy, 2018, 17, 621-627.	0.5	10
129	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. Tomography, 2020, 6, 261-271.	1.8	10
130	Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer. Journal of Oncology Practice, 2014, 10, e360-e367.	2.5	9
131	Definitive Chemoradiotherapy ("Watch-and-Wait―Approach). Seminars in Radiation Oncology, 2016, 26, 205-210.	2.2	9
132	Stereotactic Body Radiation Therapy for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 290-295.	2.0	9
133	The impact of young adult colorectal cancer: incidence and trends in Colorado. Colorectal Cancer, 2017, 6, 49-56.	0.8	9
134	Characterizing Spatial Lung Function for Esophageal Cancer Patients Undergoing Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 738-746.	0.8	9
135	Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?. Oncologist, 2020, 25, e1249-e1250.	3.7	9
136	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. JCO Precision Oncology, 2021, 5, 317-324.	3.0	9
137	Successful Treatment of Esophageal Cancer with Airway Invasion with Induction Chemotherapy and Concurrent Chemoradiotherapy. Journal of Thoracic Oncology, 2009, 4, 432-434.	1.1	8
138	Are fiducial markers useful surrogates when using respiratory gating to reduce motion of gastroesophageal junction tumors?. Acta OncolÅ ³ gica, 2016, 55, 1040-1046.	1.8	8
139	Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. International Journal of Radiation Oncology Biology Physics, 2021, 109, 186-200.	0.8	8
140	Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities. Chinese Clinical Oncology, 2017, 6, 28-28.	1.2	8
141	Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?. Journal of Gastrointestinal Oncology, 2015, 6, 53-9.	1.4	8
142	ACR Appropriateness Criteria® Resectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 109-117.	1.3	7
143	Evaluation of respiratory motion-corrected cone-beam CT at end expiration in abdominal radiotherapy sites: a prospective study. Acta Oncológica, 2018, 57, 1017-1024.	1.8	7
144	Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. Journal of Gastrointestinal Oncology, 2019, 10, 712-722.	1.4	7

#	Article	IF	CITATIONS
145	Controversies in radiotherapy for pancreas cancer. Journal of Surgical Oncology, 2021, 123, 1460-1466.	1.7	7
146	Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors. International Journal of Radiation Oncology Biology Physics, 2021, 110, 217-226.	0.8	7
147	ACR Appropriateness Criteria®-Anal Cancer. Gastrointestinal Cancer Research: GCR, 2014, 7, 4-14.	0.7	7
148	Image-guided Radiation Therapy for Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 561-567.	1.3	6
149	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 828-837.	1.4	6
150	Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer?. Journal of Clinical Oncology, 2016, 34, 3724-3728.	1.6	6
151	Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 977-993.	0.8	6
152	Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT. Practical Radiation Oncology, 2019, 9, e432-e442.	2.1	6
153	Improved survival in rectal cancer patients who are treated with longâ€course versus shortâ€course neoadjuvant radiotherapy: A propensityâ€matched analysis of the NCDB. Journal of Surgical Oncology, 2019, 119, 518-531.	1.7	6
154	Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 7208-7218.	1.5	6
155	Quality Research in Radiation Oncology Analysis of Clinical Performance Measures in the Management of Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 355-362.	0.8	5
156	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 591-605.	0.8	5
157	The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. Journal of Gastrointestinal Oncology, 2019, 10, 462-473.	1.4	4
158	High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients. Colorectal Cancer, 2020, 9, CRC31.	0.8	4
159	Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. Frontiers in Oncology, 2021, 11, 614640.	2.8	4
160	Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?. JAMA Oncology, 2021, 7, 687.	7.1	4
161	A first radiotherapy application of functional bulboclitoris anatomy, a novel female sexual organ-at-risk, and organ-sparing feasibility study. British Journal of Radiology, 2021, 94, 20201139.	2.2	4
162	Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers. Current Treatment Options in Oncology, 2018, 19, 51.	3.0	3

#	Article	IF	CITATIONS
163	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 167-174.	2.3	3
164	Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma Journal of Clinical Oncology, 2012, 30, 67-67.	1.6	3
165	Impact of lung and heart dose on survival after radiotherapy for esophageal cancer Journal of Clinical Oncology, 2018, 36, 3-3.	1.6	3
166	Patient versus clinician symptom reporting during chemoradiation for rectal cancer Journal of Clinical Oncology, 2012, 30, 646-646.	1.6	3
167	Esophagogastric Junction Carcinoma: Introduction. Seminars in Radiation Oncology, 2013, 23, 1-2.	2.2	2
168	When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward. Journal of Cancer Policy, 2019, 20, 100188.	1.4	2
169	Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 361.	4.3	2
170	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on RO resection rate for borderline resectable and locally advanced pancreas cancer Journal of Clinical Oncology, 2019, 37, 370-370.	1.6	2
171	The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?. Journal of Clinical Oncology, 2020, 38, 685-685.	1.6	2
172	Non-operative management of locally advanced rectal cancer. Seminars in Colon and Rectal Surgery, 2014, 25, 22-25.	0.3	1
173	ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 520-525.	1.3	1
174	Prospective Evaluation of Endoluminal High Dose Rate Brachytherapy with Concurrent Chemotherapy for Rectal or Anal Cancer Patients: Initial Clinical Results. Brachytherapy, 2016, 15, S142.	0.5	1
175	Response to, "Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond― Radiotherapy and Oncology, 2021, 154, e17.	0.6	1
176	Mature Experiences Using Local Therapy for Oligometastases. Seminars in Radiation Oncology, 2021, 31, 180-185.	2.2	1
177	Radiation Therapy: The North American Approach. , 2019, , 365-403.		1
178	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. Gastrointestinal Cancer Research: GCR, 2013, 6, 87-9.	0.7	1
179	What is the significance of circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy?. Journal of the American College of Surgeons, 2011, 213, S115.	0.5	0
180	Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?. Current Colorectal Cancer Reports, 2013, 9, 126-129.	0.5	0

#	Article	IF	CITATIONS
181	Technical Note: Intrafractional changes in time lag relationship between anterior-posterior external and superior-inferior internal motion signals in abdominal tumor sites. Medical Physics, 2015, 42, 2813-2817.	3.0	0
182	Design of a Novel Applicator for Esophageal High Dose Rate Brachytherapy. Brachytherapy, 2015, 14, S101-S102.	0.5	0
183	Clinical Use of a Novel Balloon Based Esophageal Brachytherapy Applicator. Brachytherapy, 2016, 15, S35.	0.5	0
184	Reply to Tumor localization may change the type of adjuvant treatment in gastric cancer. Cancer, 2017, 123, 4737-4738.	4.1	0
185	The Role of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Current Cancer Therapy Reviews, 2018, 14, 46-54.	0.3	Ο
186	Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. Seminars in Radiation Oncology, 2019, 29, 137-143.	2.2	0
187	Tu1336 COMPARISON OF TRADITIONAL BACK-LOADED FIDUCIAL NEEDLES WITH PRELOADED FIDUCIAL NEEDLES IN EUS-GUIDED FIDUCIAL MARKER PLACEMENT FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) IN PATIENTS WITH PANCREATIC ADENOCARCINOMA (PC): A RANDOMIZED CONTROLLED TRIAL (RCT). Gastrointestinal Endoscopy, 2019, 89, AB577-AB578.	1.0	О
188	Non-surgical "Watch and Wait―Approach to Rectal Cancer. Current Colorectal Cancer Reports, 2020, 16, 118-124.	0.5	0
189	Reply to M. Ratain. JCO Precision Oncology, 2021, 5, 937-938.	3.0	Ο
190	Radiation in Rectal Cancer: What Are the Options and If/When Can It Be Avoided?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 219-221.	3.8	0
191	Stereotactic Body Radiation Therapy for Liver Metastases: Radiation Therapy Planning. , 2017, , 229-238.		0
192	Radiation Therapy for Liver Metastases. , 2018, , 311-322.		0
193	Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC) Journal of Clinical Oncology, 2018, 36, TPS529-TPS529.	1.6	Ο
194	Early outcomes in patients with locally advanced rectal cancer following total neoadjuvant therapy Journal of Clinical Oncology, 2018, 36, 848-848.	1.6	0
195	Impact of radiation dose during neoadjuvant chemoradiation on postoperative complications in esophageal (EC) and gastroesophageal junction cancers (GEJC) Journal of Clinical Oncology, 2019, 37, 119-119.	1.6	Ο
196	Concurrent versus sequential neoadjuvant chemoradiation therapy for esophageal and gastroesophageal junction adenocarcinoma Journal of Clinical Oncology, 2020, 38, 395-395.	1.6	0
197	Management of a locally advanced rectal cancer in a patient who declined surgery. Gastrointestinal Cancer Research: GCR, 2012, 5, 205-9.	0.7	0
198	Tailoring Distress Screening in Oncology Populations: <i>Timing distress screening in surgically resectable esophageal cancer</i> . Oncology Issues, 2021, 36, 30-35.	0.1	0